We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock
ONCT

Delisted

ONCT was delisted on the 2nd of December, 2024.

Back to rankings

58 hedge funds and large institutions have $11.5M invested in Oncternal Therapeutics, Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 24 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

0% more funds holding

Funds holding: 58 → 58 (0)

33% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 24

35% less capital invested

Capital invested by funds: $17.8M → $11.5M (-$6.25M)

46% less call options, than puts

Call options by funds: $266K | Put options by funds: $497K

Holders
58
Holders Change
–
Holders Change %
0%
% of All Funds
1.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
16
Reduced
24
Closed
10
Calls
$266K
Puts
$497K
Net Calls
-$231K
Net Calls Change
-$173K

Top Buyers

Rank Fund Capital Flow
1
TC
TFS Capital
Pennsylvania
+$620K
2
BIT
BlackRock Institutional Trust
California
+$549K
3
Charles Schwab
Charles Schwab
California
+$128K
4
TCIM
TIAA CREF Investment Management
New York
+$103K
5
WMSA
Weiss Multi-Strategy Advisers
New York
+$98.4K

Top Sellers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
-$1.18M
2
VM
VHCP Management
New York
-$1.01M
3
OIM
Oracle Investment Management
Connecticut
-$597K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$501K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$496K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jacobs Levy Equity Management
26
Jacobs Levy Equity Management
New Jersey
$61K +$61.8K +27 New
DekaBank Deutsche Girozentrale
27
DekaBank Deutsche Girozentrale
Germany
$60K +$2.29K +1 +4%
DT
28
Diversified Trust
Tennessee
$50K -$126K -55 -72%
SO
29
STRS Ohio
Ohio
$50K -$4.58K -2 -8%
VKH
30
Virtu KCG Holdings
New York
$50K +$22.9K +10 +83%
SAM
31
Summit Asset Management
Tennessee
$46K +$22.9K +10 +100%
PPA
32
Parametric Portfolio Associates
Washington
$43K +$43.5K +19 New
RhumbLine Advisers
33
RhumbLine Advisers
Massachusetts
$42K – – –
BA
34
BlackRock Advisors
Delaware
$41K -$45.7K -20 -53%
BCM
35
Bridgeway Capital Management
Texas
$41K – – –
CAN
36
Cetera Advisor Networks
California
$40K -$41.2K -18 -50%
Citigroup
37
Citigroup
New York
$40K -$2.29K -1 -6%
CS
38
Credit Suisse
Switzerland
$39K -$126K -55 -76%
Morgan Stanley
39
Morgan Stanley
New York
$37K -$108K -47 -75%
RIM
40
Reliant Investment Management
Tennessee
$36K +$34.3K +15 New
NFA
41
Nationwide Fund Advisors
Ohio
$35K – – –
U
42
UBS
Switzerland
$32K +$32K +14 New
Renaissance Technologies
43
Renaissance Technologies
New York
$30K +$29.7K +13 New
GC
44
Guggenheim Capital
Illinois
$29K +$11.4K +5 +71%
AIG
45
American International Group
New York
$28.7K -$4.58K -2 -14%
Wells Fargo
46
Wells Fargo
California
$27K – – –
TAM
47
Telluride Asset Management
Minnesota
$22K +$20.6K +9 New
TRCT
48
Tower Research Capital (TRC)
New York
$19K +$2.29K +1 +14%
Two Sigma Investments
49
Two Sigma Investments
New York
$19K +$18.3K +8 New
OC
50
Oppenheimer & Co
New York
$17K – – –
1
2
3

ONCT Hedge Fund Activity: Q4 2013 in Review

58 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2013, worth a combined $11.5M — down 35% from $17.8M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ONCT positions and 10 closed out — a net gain of 1 holder — while 16 added to existing stakes and 24 trimmed.

The largest buyer was TFS Capital, adding an estimated $620K. The largest seller was BlackRock Fund Advisors, cutting an estimated $1.18M.

  • 58 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2013, unchanged from Q3 2013.
  • Funds reported $11.5M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2013, down 35% quarter-over-quarter.
  • 11 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2013 and 10 closed out, a net change of +1 holder.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2013 was TFS Capital, an estimated $620K added.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2013 was BlackRock Fund Advisors, an estimated $1.18M sold.

Based on aggregated 13F filings for Q4 2013.